Evolution of Biologics Screening Technologies
Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug d...
Main Authors: | Matthew J. Gardener, Peter Cariuk, Tristan J. Vaughan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-05-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/6/5/681 |
Similar Items
-
siMacro: A Fast and Easy Data Processing Tool for Cell-Based Genomewide siRNA Screens
by: Nitin Kumar Singh, et al.
Published: (2013-03-01) -
The Deconstructed Granuloma: A Complex High-Throughput Drug Screening Platform for the Discovery of Host-Directed Therapeutics Against Tuberculosis
by: Lu Huang, et al.
Published: (2018-08-01) -
Validation of a modified fluorimetric assay for the screening of trichomonacidal drugs
by: Alexandra Ibáñez Escribano, et al.
Published: (2012-08-01) -
High-throughput screening assay used in pharmacognosy: Selection, optimization and validation of methods of enzymatic inhibition by UV-visible spectrophotometry
by: Graciela Granados-Guzmán, et al.
Published: (2014-02-01) -
Quality control of cell-based high-throughput drug screening
by: Zhiyun Zhang, et al.
Published: (2012-10-01)